Home › Triple-Negative Breast Cancer › Ohio › Columbus
Triple-Negative Breast Cancer clinical trials in Columbus, OH
16 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RecruitingPhase 1
- Ohio State University Comprehensive Cancer Center, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- The Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Local Institution - 0102, Columbus
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Ohio State University, Columbus
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- Ohio State University CRS, Columbus
- Ohio Health Research Institute, Columbus
- Anita Stewart Oncology Center, Columbus
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RecruitingPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
RecruitingPhase 1/2
- Ohio State University, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Recruiting
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
RecruitingPhase 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingPhase 2
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecruitingPhase 2
- Ohio State University Medical Center, Columbus
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
Recruiting
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- The Ohio State University, Columbus
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Atlanta, GA20 studies
- Arlington, VA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Tampa, FL15 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer56 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Cancer (all types)38 studies
- Lung Cancer37 studies
- Acute Myeloid Leukemia35 studies
- Chronic Lymphocytic Leukemia28 studies
- Metastatic Cancer27 studies
- Endometrial Cancer25 studies
- Colorectal Cancer24 studies
- Prostate Cancer24 studies
- Multiple Myeloma24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.